Lifeboat Foundation

An interdisciplinary team is working on a revolutionary lightweight glass that is able to dynamically monitor the wearer’s vision and display contextual images that are vision-corrected. Story Image.

It is 09:30 a.m. on her ranch in Texas, and we are talking to the 30th Via Satellite Executive of the Year, Gwynne Shotwell about everything from her history at SpaceX, her relationship with its founder and CEO, Elon Musk — the man she still calls “the boss” — and what it means for her to be the recipient of our award in its 30-year anniversary. Shotwell talks honestly, will answer the tough questions, and you feel like it is a genuine conversation, rather than a series of scripted answers that have gone through an entire communications department before you are allowed to be on the phone.

We know SpaceX is a great company. We know they are the “cool kids” of space right now and, while Elon Musk obviously takes a lot of credit for his vision and bravery to come up with SpaceX, in Shotwell he found the perfect executive to run it like a finely oiled machine. In 2016, SpaceX suffered a huge setback when a high-profile test failure led to the loss of the Spacecom satellite Amos 6, making headlines across the world. It is said we learn more about ourselves when we deal with adversity, and this would be the case with Shotwell and SpaceX. She fronted up, and led the team back from this demoralizing setback to unprecedented heights in 2017. She is one of the most admired and respected executives in our industry, and an inspiration for young women around the world. When it came to selecting our 30th Satellite Executive of the Year, there was really only one choice this time around, SpaceX President and COO, Gwynne Shotwell is our Satellite Executive of the Year 2017.

SGLT2 inhibitors, a promising class of diabetes drugs, were shown to significantly lower the rates of heart failure and death in the large CVD-REAL study.

Summary: A team of scientists at Tongji University just announced a breakthrough in regenerating human lungs using stem cells, improving lung function in patients. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

A team of researchers from Tongji University in China announced what they say is a breakthrough in treating lung diseases by regenerating tissue using stem cell transplantation.

In a pilot clinical trial, the treatment proved effective at repairing the lung tissue of two patients suffering from lung diseases, who showed improvements in both symptoms and on CT scans, say the researchers. Zuo Wei is a Tongji University professor who led the research team and says.

Continue reading “Researchers report breakthrough in human lung regeneration” »

Summary: A research team at UCSD discovered a key enzyme that plays a role in burning calories during both obesity and dieting and sabotages weight loss. Moreover, these scientists may have just found an existing drug that counteracts this enzyme. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

Ever wonder why dieting often leads to a plateau in weight loss? It happens because the body is trying to maintain a steady weight by regulating the expenditure of energy. How this happens has remained a mystery until now.

In a paper published on February 8 in the journal Cell, a team of researchers at the University of California San Diego (UCSD) School of Medicine led by Alan Saltiel, Ph.D. has identified a key enzyme that sabotages weight loss efforts during dieting. Dr. Saltiel is the director of UCSD’s Institute for Diabetes and Metabolic Health, and says.

Continue reading “Researchers discover key enzyme sabotaging our weight loss” »

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

Continue reading “AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease” »

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

Continue reading “Researchers create functioning kidney tissue” »

Researchers just reported promising rapamycin clinical trial results in the first of its kind test of the drug’s safety and anti-aging effects on healthy Senior adults. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

A rapamycin clinical trial using healthy adults recently completed and reported the drug to be safe over the short-term when used for anti-aging purposes.

This clinical trial of rapamycin was one of the first testing the compound’s safety as an anti-aging drug in healthy Seniors. The clinical trial consisted of 25 healthy older adults 70–95 years between the ages of 70 to 95. The study participants took either a placebo or 1mg rapamycin daily for eight weeks. The main finding of the study was that the drug was safe, without significant side effects. The researchers published their results on February 3 in the journal Experimental Gerontology and concluded.

Continue reading “Researchers report promising anti-aging rapamycin clinical trial results” »

A Japanese scientist regrows hair follicles at record rate using a special ingredient – this novel technique could revolutionize the treatment of baldness. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

While scientists aim to lengthen our lifespans, at least they can lengthen our locks.

Or even grow a full head of hair on a bald pate, in the near future.